Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances

Core Viewpoint - Intuitive Surgical, Inc. (NASDAQ:ISRG) is highlighted as a top healthcare AI stock, with a reaffirmed Buy rating and a price target of $655 from Robert W. Baird, while Citi has assigned a Hold rating [1][2]. Group 1: FDA Clearances and Product Expansion - On December 10, Intuitive Surgical announced FDA clearance for its da Vinci Single Port (SP) surgical system for three additional procedures: inguinal hernia repair, cholecystectomy, and appendectomy, expanding its US indications [3]. - The da Vinci SP system allows surgeons to perform complex operations through a single incision or natural orifice, building on previous FDA clearances for various procedures [4]. - The da Vinci SP system has been approved for a wider range of procedures outside the US, including in Europe, Japan, and Korea, with initial US clearances focusing on urology [4]. Group 2: Company Overview - Intuitive Surgical, Inc. develops, produces, and markets robotic systems for minimally invasive surgery, providing instruments, accessories, and services to support these platforms, which are installed in over 10,000 hospitals globally [5].